Core Viewpoint - MicroPort Medical announced the publication of the TARGET-FIRST clinical study results for its Firehawk® drug-eluting stent system in the New England Journal of Medicine, highlighting a significant reduction in dual antiplatelet therapy duration for low-risk acute myocardial infarction patients without increasing ischemic risk [1] Group 1 - The Firehawk® stent allows for a reduction in dual antiplatelet therapy (DAPT) duration from 12 months to 1 month for patients achieving complete revascularization [1] - The study results were presented at the European Society of Cardiology 2025 Congress in Spain, under the "Latest Breakthrough Clinical Trials (HOT LINE)" session [1] - The shortened DAPT duration not only does not increase ischemic risk but also significantly reduces bleeding complications [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* Firehawk®╱火鷹®支架先前的一項歐洲臨床試驗TARGET AC，曾因解決了晚期血栓這一困惑醫學界 多年的難題而在全球頂級期刊《柳葉刀》發表，並引發了對該中國造產品的全球性關注。在歐洲實施 的兩個完全獨立的大規模臨床研究，不僅證實了Firehawk®╱火鷹®支架的臨床獲益，也佐證了其有一 定的經濟性潛力和人道化優勢。因其具備了實質性影響心血管領域臨床實踐和綜合治療策略的關鍵 因素，Firehawk®╱火鷹®支架有望成為破局「高品質－經濟性－可及性」不可能三角的稀有醫療方案之 一。本集團始終致力於研發創新型醫療器械和技術，並與世界一流的研究人員合作，讓中國造產品 在世界舞台上依靠數字大膽說話，以堅實的臨床證據驗證安全性和有效性，讓更多患者得以受益於 我們的技術。 關於Firehawk®╱火鷹®支架 Firehawk®╱火鷹®支架是本集團自主研發的第三代冠脈藥物洗脫支架系統，兼具 ...

报告期内，集团面对复杂多变的地缘政治及国际贸易冲突、医保费用精细化管理的持续推进、部分业务 集采执行落地晚于预期等外部挑战，以及集团近年密集获批新产品尚处于准入及/或培育期、产品结构 短期调整带来的新旧动能衔接存在一定时滞性等影响，集团收入增长阶段性承压，报告期内，录得收入 5.48亿美元，同比下降2.2%(剔除汇率影响)。 格隆汇8月30日丨微创医疗(00853.HK)发布公告，截至2025年6月30日止六个月，实现收益5.48亿美元， 同比减少2.2%；公司权益股东应占亏损为4660.2万美元，上年同期公司权益股东应占亏损为9683万美 元；基本每股亏损2.53美分。 ...

公告称，亏损收窄主要得益于报告期内，集团销售、管理、研发三项费用总金额较2024年同期缩减 14.5%，运营费率同比优化8.1个百分点，其中研发费率由20.6%下降至13.2%。集团于报告期内完成数家 非核心业务处置，为集团带来2610万美元的正向收益。 微创医疗(00853)公布2025年中期业绩，收入约5.475亿美元，同比减少2%;公司权益股东应占亏损4660.2 万美元，同比减亏51.9%;每股基本亏损2.53美分。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 截至二零二五年六月三十日止六個月的未經審核中期業績公告 財務摘要 | | | 截至六月三十日止六個月 | | | --- | --- | --- | --- | | | 二零二五年 | 二零二四年 | 變動百分比 | | | 千美元 | 千美元 | % | | | （未經審核） | （未經審核） | | | 收入 | 547,532 | 558,702 | 減少2.2% | | | | | （剔除匯率影響） | | 期間利潤╱（虧損） | (36,361) | (106,674) | 減虧65.9% | | 公司權益股東應佔利潤╱（虧損） | (46,602) | (96,830) | 減虧51.9% | | 每股利潤╱（虧損）－ | | | | | 基本（美分） | (2.53) | (5.29) | 減虧52.2% ...

微创医疗(00853)公布心脉医疗科技2025年上半年业绩，收入约7.14亿元，同比减少9.24%;归属于心脉医 疗科技股权持有人的净利润约3.15亿元，同比减少22.03%。 ...

Group 1 - The core viewpoint of the article highlights the financial performance of MicroPort Medical Technology for the first half of 2025, indicating a decline in both revenue and net profit compared to the previous year [1] Group 2 - The revenue reported by MicroPort Medical Technology is approximately 714 million yuan, representing a year-on-year decrease of 9.24% [1] - The net profit attributable to shareholders of MicroPort Medical Technology is around 315 million yuan, showing a year-on-year decline of 22.03% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 海外監管公告 本海外監管公告乃根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.10B條刊 發。 中國上海，二零二五年八月二十六日 於本公告日期，本公司之執行董事為常兆華博士；本公司之非執行董事為白藤泰司先生、蘆田典裕 先生、孫維琴女士；及本公司之獨立非執行董事為周嘉鴻先生、劉國恩博士及邵春陽先生。 * 僅供識別 1 請參閱隨附上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）於上海證券交易所科創板 （「科創板」）刊發之公告（「該公告」），內容有關其二零二五年半年度報告。 心脈醫療科技為一家於科創板上市之公司。於本公告日期，本集團持有心脈醫療科技已發行股本約 40.32%及其業績於本公司財務報表合併入賬。 於聯交所網站登載該公告，僅為向香港投資者進行同等的資訊傳達及遵守上市規則第13.1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 承董事會命 以下所載為上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）截至二零二五年六月三十日 止六個月的未經審核財務資料。本集團持有心脈醫療科技40.32%的股權，其業績綜合入賬至本公司 財務報表。心脈醫療科技的股份在上海證券交易所科創板上市。 | | 截至二零二五年 | 截至二零二四年 | | | --- | --- | --- | --- | | | 六月三十日止 | 六月三十日止 | | | | 六個月 | 六個月 | 變動 | | | 人民幣千元 | 人民幣千元 | 百分比 | | 收入 | 714,429.78 | 787,174.66 | -9.24 | | 利潤總額 | 366,935.69 | 471,155.24 | -22.12 | | 歸屬於心脈醫療科技股權持有人的淨利潤 | 314,647.22 | 403,523.61 | -22.03 | | | 截至二零二五年 ...

Investment Rating - The report does not explicitly state an investment rating for the laparoscopic surgical robot industry Core Insights - The laparoscopic surgical robot industry is characterized by high technological barriers, long R&D cycles, and strict regulatory oversight, with significant growth driven by domestic breakthroughs and reduced procurement costs. The competitive landscape is expected to evolve towards a "duopoly + niche specialization" model in the long term [4][41][42] Industry Overview - Laparoscopic surgical robots combine endoscopic technology with robotic systems, primarily used in urology, gynecology, and general surgery, offering advantages such as minimal invasiveness and rapid recovery [4][5] - The industry is classified into two main categories based on surgical techniques: multi-port and single-port laparoscopic surgical robots [5] Industry Characteristics - The industry features long R&D cycles and strict regulatory requirements, with the registration process for high-risk medical devices typically taking over five years [6][7] - High levels of industry collaboration are evident, with the integration of precision manufacturing, sensor control, image recognition, and biomaterials [8] - The technological complexity and high patent protection create significant barriers to entry, with a focus on multi-disciplinary collaboration and sustained capital investment [9] Development History - The industry has evolved through three stages: the embryonic phase (1985-2000), the initiation phase (2000-2021), and the rapid development phase (2021-present), with significant advancements in technology and market acceptance [10][11][12][13][15] Market Size and Growth - The market size for laparoscopic surgical robots in China was approximately 3.12 billion RMB in 2022, projected to reach 9.84 billion RMB by 2026, with a CAGR of 33.3% [37][38] - The growth is attributed to domestic production breakthroughs that significantly lower procurement costs, leading to increased hospital purchases [38][39] Competitive Landscape - The market is witnessing an influx of domestic companies, with over 10 models approved for market entry by the end of 2024, leading to intensified competition and potential market consolidation [41] - A high-end competitive landscape is emerging, with established players like Intuitive Surgical's da Vinci system dominating the market, while domestic brands like MicroPort's TiMai are gaining traction [42] Supply Chain Analysis - The supply chain consists of upstream component suppliers, midstream manufacturers, and downstream clinical applications, with the performance of upstream components directly impacting the overall system capabilities [16][17] - The midstream segment is critical, with leading manufacturers focusing on system integration and production, while the downstream segment involves hospital procurement and clinical application [19][30] Conclusion - The laparoscopic surgical robot industry is poised for rapid growth, driven by technological advancements, regulatory support, and increasing acceptance among healthcare providers, with a clear trend towards domestic innovation and market diversification [40][41]